Core Viewpoint - A class action lawsuit has been filed against Apple Inc. for allegedly making false and misleading statements regarding the integration of advanced AI-based features into its devices, which may have impacted investor decisions during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Apple securities between June 10, 2024, and June 9, 2025 [1]. - Allegations include that Apple misstated the timeline for integrating advanced AI features into devices, leading to overstated business and financial prospects [5]. - The lawsuit claims that the lack of advanced features would negatively affect iPhone 16 sales, resulting in damages to investors when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Apple securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in 2019 and 2020 [4].

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025 [1] Group 1: Class Action Details - The class period for the lawsuit is from January 13, 2021, to July 28, 2024, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt failed to warn investors that preterm infants were at an increased risk of developing necrotizing enterocolitis (NEC) from consuming its cow's milk-based formula, Enfamil [5] - It is claimed that Reckitt did not disclose the potential impact on sales of Enfamil and the company's exposure to legal claims, leading to materially false and misleading statements about its business and operations [5]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation for alleged misleading statements and failure to disclose critical information regarding its business performance during the specified Class Period from August 13, 2024, to May 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [5]. - It is alleged that updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [5]. - The lawsuit asserts that the public statements made by 3D Systems were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased 3D Systems securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 12, 2025, to represent other class members in the litigation [3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - The firm emphasizes the importance of selecting qualified legal counsel with proven success in securities litigation [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 1, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - It is claimed that the viability of Fortrea's post-Spin-Off business model and its financial prospects were overstated, resulting in material misstatements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to allegations that Elevance Health made false or misleading statements regarding the impact of Medicaid redetermination on its financial guidance and cost trends [4]. - The lawsuit claims that Elevance misrepresented the adequacy of premium rates negotiated with states, failing to disclose the rising acuity and utilization of Medicaid members [4]. - Investors are encouraged to join the class action by contacting Rosen Law Firm, with a lead plaintiff application deadline set for July 11, 2025 [2][5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [3]. - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, Inc. for misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand, with a lead plaintiff deadline set for July 15, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Krispy Kreme made false and misleading statements about the demand for its products at McDonald's locations, which significantly declined after the initial marketing launch [4]. - It is claimed that the declining demand at McDonald's was a key factor in the drop in average sales per door per week, and that the partnership with McDonald's was not profitable [4]. - The lawsuit states that these issues posed a substantial risk to maintaining the partnership with McDonald's and led to a pause in Krispy Kreme's expansion into new locations [4]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions of dollars for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [3]. Group 3: Participation Information - Investors who purchased Krispy Kreme securities during the class period can join the class action without any out-of-pocket fees through a contingency fee arrangement [1][2]. - Interested parties can find more information and join the class action by visiting the provided link or contacting the firm directly [2][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol without informing shareholders, leading to artificially inflated stock prices, which resulted in investor damages when the true information was revealed [5].

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Vestis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the company overbilled customers for ad impressions served to declared bots and that its risk disclosures were materially false and misleading [5]. - The lawsuit asserts that the defendants' positive statements about DoubleVerify's business lacked a reasonable basis, leading to investor damages when the true details emerged [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].